HOME >> BIOLOGY >> NEWS
Targeting key proteins of carcinogenesis

among experts.

A prerequisite for the E3-independent reaction is the presence of a Ub-binding domain (UBD) in the protein that is able to recognize Ub. This type of protein is of utmost importance for the cell because it can distinguish between ubiquitinated and non-ubiquitinated proteins, explains Dr. Daniela Hoeller, the responsible scientist. UBD-proteins are the key to the effects of Ub both in normal and malignant cells.

Dikic and his coworkers demonstrated that proteins equipped with an UBD can ubiquitinate themselves by directly recruiting Ub-loaded E2 enzymes thus making E3 ligases dispensible. In their previous work Hoeller and Dikic showed that the ubiquitination of UBD proteins does not lead to their degradation but rather causes their functional inactivation. In other words they become unable to recognize and control ubiquitinated proteins. If needed the cell can re-activated them by cleaving the attached Ub. In this way the cell can quickly and dynamically react on external signals.

The discovery provides the basis for novel therapeutic approaches that are more specific than drugs like Bortezomib. For an effective therapeutic use there is still a long way to go, explains Mller-Esterl, who needs to update his biochemistry textbook now.


'"/>

Contact: Ivan Dikic
ivan.dikic@biochem2.de
49-696-301-4862
Johann Wolfgang Goethe-Universitt Frankfurt
22-Jun-2007


Page: 1 2

Related biology news :

1. Targeting tumors the natural way
2. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
3. Targeting tau: Inflammation study suggests new approach for fighting Alzheimers
4. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
5. Targeting wolbachia, doxycycline reduces pathology of lymphatic filariasis
6. Targeting lung cancer
7. Targeting the dosage compensation complex
8. Targeting pancreatic cancer
9. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
10. Targeting tumor growth
11. UCF research links proteins, stem cells and potential Alzheimers treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
(Date:1/18/2016)... SAN JOSE, Calif. , Jan. 18, 2016 ... storage security software that simplifies the use and ... a technology and go-to-market partnership with American Cyber.  ... "American Cyber brings extensive experience leading transformational C4ISR ... missions implementing and integrating the latest proven technology ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... leading supplier of Semantic Graph Database technology has been recognized As “ Best ... by Corporate America Magazine. , “At Corporate America, it’s our priority to showcase ...
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
Breaking Biology Technology:
Cached News: